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Glucose metabolism is altered in long-lived people and mice.
Although it is clear that there is an association between altered
glucose metabolism and longevity, it is not known whether this
link is causal or not. Our current hypothesis is that decreased
fasting glucose utilization may increase longevity by reducing
oxygen radical production, a potential cause of aging. We
observed that whole body fasting glucose utilization was lower
in the Snell dwarf, a long-livedmutantmouse.Whole body fast-
ing glucose utilization may be reduced by a decrease in the pro-
duction of circulating glucose. Our isotope labeling analysis
indicated both gluconeogenesis and glycogenolysis were sup-
pressed in Snell dwarfs. Elevated circulating adiponectin may
contribute to the reduction of glucose production in Snell
dwarfs. Adiponectin lowered the appearance of glucose in the
media over hepatoma cells by suppressing gluconeogenesis and
glycogenolysis. The suppression of glucose production by adi-
ponectin in vitro depended on AMP-activated protein kinase, a
cell mediator of fatty acid oxidation. Elevated fatty acid oxida-
tion was indicated in Snell dwarfs by increased utilization of
circulating oleic acid, reduced intracellular triglyceride content,
and increased phosphorylation of acetyl-CoA carboxylase.
Finally, protein carbonyl content, a marker of oxygen radical
damage,was decreased in Snell dwarfs.The correlation between
high glucose utilization and elevated oxygen radical production
was also observed in vitro by altering the concentrations of glu-
cose and fatty acids in themedia or pharmacologic inhibition of
glucose and fatty acid oxidation with 4-hydroxycyanocinnamic
acid and etomoxir, respectively.
Glucosemetabolism is altered in centenarians and long-lived
mice (1–8). Our current hypothesis is that a decrease in fasting
glucose utilization may increase longevity by lowering oxygen
radical production, a potential cause of aging. Changes in glu-
cose metabolism have been indicated in long-lived rodents by
(a) oral glucose tolerance test, (b) insulin tolerance test, (c) inhi-
bition of glucose production and stimulation of glucose dis-
posal under euglycemic clamp conditions, and (d) the levels of
circulating glucose and insulin under physiologic conditions
(9–13). These methods suggest that glucose utilization is ele-
vated in long-lived mice during feeding. However, they do not
reveal whether glucose utilization is lower in long-lived mice
during fasting, a period of the day when glucose utilization is
relatively low and fatty acid utilization is high.
During fasting (a) the appearance in the circulation of glu-
cose from the gastrointestinal tract is low, (b) the concentra-
tions of circulating glucose and insulin are low, (c) circulating
glucose is used for energy rather than storage, and (d) the cir-
culating glucose used is replenished largely by liver glucose pro-
duction, via gluconeogenesis and glycogenolysis. Thus, whole
body glucose utilization may be lowered during fasting by
decreasing glucose production. Whether fasting glucose pro-
duction is decreased in long-lived mice is currently unknown.
Adiponectin, a hormone produced by adipose tissue, can
lower glucose utilization by decreasing glucose production
(14–16). Adiponectin is elevated in many long-lived mice (17,
18). The elevation of adiponectin in long-lived mice may also
stimulate fatty acid utilization through its intracellular target,
AMP-activated protein kinase (AMPK)3 (19–21).
Reducing the utilization of glucose for energy may increase
longevity by lowering the production of oxygen radicals from
the mitochondria (22, 23). The link between glucose utilization
and oxygen radical production is demonstrable in bovine aortic
endothelial cells (24). Compared with 5 mM glucose, the incu-
bation of aortic endothelia in 30mM glucose doubled the rate of
glucose utilization and tripled reactive oxygen species. The ele-
vation of reactive oxygen species by 30mM glucose was blocked
by 4-hydroxycyanocinnamic acid (4-OHCA), an inhibitor of
pyruvate transport into the mitochondria. The link between
low glucose utilization and longevity is supported by the obser-
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vation that fasting glucose utilization in mice, rats, dogs, and
humans, respectively, 20, 12, 4, and 2 mg/kg/min, correlates
with the difference in longevity between these species (25–28).
In the present study, we set out to determine whether fasting
glucose utilization is reduced in long-lived mice. We measured
glucose utilization after food withdrawal in free moving long-
lived Snell dwarf mice (29). We also investigated the mecha-
nisms underlying the reduction of glucose utilization and
whether low glucose andhigh fatty acid utilization could reduce
oxygen radical production.
EXPERIMENTAL PROCEDURES
MouseModels—Allmicewere 4- to 7-month-oldmales. Snell
dwarf and control mice were food-deprived after 7 a.m. and all
measurements were made at 1–3 p.m. Snell dwarf and control
mice were F1 hybrids from female DW/J (Pit1dw/), and male
C57Bl/6J (Pit1dw/) Snell dwarfs were housed with controls.
Adiponectin transgenic mice were previously described (16).
Autoclaved NIH3 chow (Diet 96WA: 73% carbohydrate, 18%
protein, 4% fat, 5% ash) and acidified water were provided.
Temperature (23 °C), humidity (55%), and a 12-h light/12-h
dark cycles were strictly controlled. Procedures were approved
by the Institutional Animal Care and Use Committees of the
Jackson Laboratories and the University of North Carolina.
Glucose Utilization in Vivo—Due to the small size of Snell
dwarf mice, glucose utilization was measured by single injec-
tion of tracer instead of the primed infusion technique (30).
Trace amounts of carbon-3-labeled [3H]glucose (PerkinElmer
Life Sciences) in saline (50–100 l) were injected directly into
the circulation of conscious freemovingmice through the oph-
thalmic plexus (31). Blood samples (10–20 l) were collected
from the tail tip at 3, 6, 9, 12, 15, 18, and 21 min after injection
for the measurement of (a) glucose by a hand-held glucose
meter and (b) radioactivity by scintillation counter (15, 16). The
glucose meter (Johnson & Johnson) showed comparable accu-
racy and reproducibility to colorimetric assays. High-perfor-
mance liquid chromatography analysis was performed to verify
that the radioactivity measured in dried plasma by scintillation
counter represented [3H]glucose. We used an Agilent 1100
high-performance liquid chromatography system connected to
a beta-RAM Model 2B Detector (IN/US Systems) and an
Aminex HPX-87C polystyrene divinylbenzene resin column
(Bio-Rad) at 80 °C using a 0.6 ml/min flow of water. Blood col-
lected immediately before [3H]glucose injection was used to
measure insulin and adiponectin by radioimmunoassay (Linco)
and Western blot analysis, respectively (17). Mutant and con-
trol mice were always paired for the measurement of glucose
utilization.
Calculations—The disappearance of radioactivity in plasma
exhibited single phase exponential kinetics according to
ln(Ei) kt ln(Eo), where Ei is [3H]glucose in plasma at time
i, k is the fractional elimination constant (min1), t is the time
after [3H]glucose injection (min), and Eo is the initial [3H]glu-
cose in plasma at time 0. Glucose utilization was calculated by
multiplying k with the total pool of circulating glucose (Q) and
dividing by the body weight (32). The pool of circulating glu-
cose was estimated from the initial dilution of the tracer.
Contribution of Gluconeogenesis and Glycogenolysis to Glu-
cose Production—Plasma glucose produced by gluconeogenesis
and glycogenolysis was measured in free moving Snell dwarf
and control mice by measuring 2H enrichment of plasma glu-
cose on carbons 5 and 2 (33). Enrichment (5%) of body water
by 2H2O was achieved by intraperitoneal injection of 2H2O
(0.015  body weight) and the provision of 5% 2H2O drinking
water at 10 a.m. The 2H2O enrichment of body water was con-
firmed by mixing plasma, collected 1–3 p.m., with calcium car-
bide to form acetylene gas (34). Acetylene gas was analyzed by
GC/MSusing an EC5Alltech Econo-CAP column (30m 0.32
mm, film thickness of 1 m) at 200 °C. Acetylene and
[2H]acetylene were measured by monitoring m/z 26 and 27,
respectively. To measure 2H enrichment of circulating glucose
on carbons 5 and 2, plasma (100 l) was deproteinated by
ZnSO4/Ba(OH)2 and deionized through an AG-1-X8 (COO
form) over an AG-50W-X8 (H form) resin column (Bio-Rad).
For the measurement of 2H labeling of glucose on carbon 5,
glucose (50 g) was converted to xylose. Oxidation yielded
formaldehyde that contained carbon 5 of glucose and its hydro-
gen. Six formaldehydes in NH4OHwere condensed to produce
solid hexamethylenetetramine (HMT). HMT was dissolved in
dichloromethane and analyzed byGC/MSusing anEC5Alltech
Econo-CAP column (30 m  0.32 mm, film thickness of 1 m)
operated at 60 °C for 1 min followed by an increase to 300 °C at
10 °C/min under 2 ml/min He2 gas. HMT and [2H]HMT were
measured by single ion monitoring ofm/z 140 and 141, respec-
tively. For themeasurement of 2H labeling of glucose on carbon
2, glucose (10–20g) was reduced to sorbitol withNaHB4. The
hydrogen on carbon 2 was transferred to lactate using sorbitol
dehydrogenase and lactate dehydrogenase (Sigma). Lactate was
derivatized and analyzed by GC/MS using a Pal A200 autosam-
pler (Leap) and a Trace GC-2000 attached to a TSQ 7000 mass
analyzer (ThermoFinnigan) under He2 gas (2 ml/min). In vivo
measurements of gluconeogenesis were estimated by using car-
bon 5/carbon 2 enrichment instead of carbon 5/body water
2H2O to eliminate the diluting effect of glucose absorption from
the gastrointestinal tract.
Glucose in Stomach Contents—Stomach contents were iso-
lated from Snell dwarf and control mice after euthanasia and
analyzed for glucose (35). In brief, stomach contents (50–250
mg) were digested in 1 N NaOH, and protein was precipitated
out with 1 N perchloric acid. Glycogen was precipitated out of
solution in ethanol and digested with 1 mg/ml amyloglucosi-
dase (Sigma) in 0.5 M sodium acetate (pH 4.5) for 4 h at 55 °C
before glucose was measured by colorimetric assay (Waco).
Body Composition—Percent body fat and body water were
measured in conscious mice by magnetic resonance imaging
using an Echo magnetic resonance imaging-100 QNMR sys-
tem. Percentages of body fat and body water were also esti-
mated from the radioactivity in a sample of plasma 1 h after
3H2O injection for verification.
Glucose Production in Vitro—Glucose production in
McArdle 7777 rat hepatoma cells was determined as previously
described with minor modifications (14). Cells were thawed
from liquid nitrogen storage upon rat tail collagen I-coated
plates. Cells equilibrated for 24 h in high glucose (25 mM) Dul-
becco’s Modified Eagle Medium (DMEM) supplemented with
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2.5% fetal bovine serum (FBS) and 2.5% horse serum (HS). After
equilibration, cells were split into 12-well plates at a density of
2.5  104 cells/well and allowed 2–3 h for adherence. The
media was changed to serum-free low glucose (5 mM) DMEM.
After 8 h, adipocyte conditionedmedia (ACM) with or without
adiponectin (ACM-adiponectin) was added. Media and cell
lysates were collected 8 h later. Colorimetric assay kits were
used to determine glucose in themedia (Waco) and cell protein
content (Pierce). ACM-adiponectin was produced by depleting
adiponectin from ACM by immunoprecipitation using rabbit
antisera produced with the peptide antigen EDDVTTTEELA-
PALV, representing adiponectin residues 18–32. Preimmune
rabbit serum was used as a control.
Retroviral Transduction in Vitro—A DNA construct encod-
ing a dominant negative AMPKmutant (DN-AMPK) was used
to generate a 5-EcoRI/3-SacII DN-AMPK fragment (36). The
fragment was cloned into a retroviral shuttle vector
pML2(EGFP-N1) producing DN-AMPK-pML2(EGFP-N1).
HEK293 cells were transfected with a 3:1 ratio of DN-AMPK-
pML2(EGFP-N1) and pCL-Eco, encoding the ecotropic enve-
lope protein (Imgenex), using FuGENE transfection reagent
(Roche Applied Science). HEK293 cells were incubated at 37 °C
for 48 h. Media was changed, and cells were placed at 32 °C for
48 h to allow for retroviral production. The media containing
virus (6 ml) was mixed with Polybrene (2.67 g) and centri-
fuged at 3500 rpm for 5 min at room temperature. The super-
natant was introduced to actively growing hepatoma cells (2
ml/well of 6-well plate) for 12–18 h at 37 °C. Medium was
replaced with DMEM/FBS/HS. Overexpression of DN-AMPK
was verified by EGFP and PCR (data not shown). The
pML2(EGFP-N1) construct was used as a control for effects of
retroviral transduction.
Fatty Acid Utilization in Vivo—Trace amounts of carbon-1-
labeled [14C]oleic acid (PerkinElmer Life Sciences) were dried
under nitrogen gas and allowed to equilibrate in plasma for 1 h
at 37 °C. The utilization of circulating oleic acid was measured
in conscious free moving Snell dwarf and control mice by
injecting [14C]oleic acid directly into the circulation through
the ophthalmic plexus. Blood samples (25–50 l) were col-
lected from the tail tip at 5, 15, 30, 55, and 70min after injection
tomeasure (a) free fatty acids by colorimetric assay (Waco) and
(b) radioactivity by scintillation counting (16). To verify that the
radioactivity in plasma represented [14C]oleic acid, high-per-
formance liquid chromatography analysis was performed at
room temperature on a Zorbax SB-Aq column (Agilent) under
1.5 ml/min 90:9:1 acetonitrile:water:acetic acid. GC/MS analy-
sis revealed oleic acid represented15–16% of circulating fatty
acids in Snell dwarf and controlmice in the 0- and 70-min blood
samples (37). Snell dwarf and control mice were always paired
for themeasurement of fatty acid utilization. Themeasurement
of glucose and fatty acid utilization by [3H]glucose and
[14C]oleic injection was based on similar tracer analysis
assumptions, including: 1) the tracer is homogeneously
mixed in the circulation, 2) the tracer is metabolically indis-
tinguishable from glucose or oleic acid, and 3) the produc-
tion of [14C]oleic acid or [3H]glucose by isotope exchange is
insignificant.
Intracellular Triacylglycerol and Acetyl-CoA Carboxylase—
Intracellular triacylglycerol content in liver and heart was
determined by homogenizing freeze-clamped tissue stored at
80 °C in 2:1 chloroform/methanol. Briefly, tissue homoge-
nates were mixed with 0.9% NaCl before the lipid extract was
dried and analyzed for triacylglycerol by enzymatic colorimet-
ric assay (Waco). Liver acetyl-CoA carboxylase (ACC) and
phosphorylated ACC was measured by Western blot analysis
(17). Antibodies againstACCwere commercially available (Cell
Signaling).
Protein Carbonyl Content—Protein carbonyl groups were
derivatized with 2,4-dinitrophenylhydrazine, producing dini-
trophenylhydrazone products that were quantified by spectro-
photometric analysis (38). Mouse liver and McArdle 7777 rat
hepatoma cells were analyzed according to the manufacturer’s
protocol for the Protein Carbonyl Assay Kit (Cayman Chemi-
cal). Mouse liver (50–150 mg) was homogenized in 2.5 M
hydrochloric acid with or without 2,4-dinitrophenylhydrazine.
Rat hepatoma cells were scraped off collagen-coated plates,
split in two tubes, and centrifuged at 14,000 rpm for 5 min at
4 °C. Cell pellets were either dissolved in 2,4-dinitrophenylhy-
drazine or 2.5 M HCl. Samples were vortexed and incubated in
the dark for 1 h at room temperature. Homogenates received
20% trichloroacetic acid and incubated on ice for 5 min. Sam-
ples were centrifuged at 14,000 rpm for 10 min at 4 °C. Pellets
were dissolved in 10% trichloroacetic acid and incubated 5 min
on ice. Samples were centrifuged at 14,000 rpm for 10 min at
4 °C. Pellets were dissolved in ethanol:ethyl acetate (1:1). Sam-
ples were centrifuged at 14,000 rpm for 10 min at 4 °C. Pellets
were resuspended in guanidine-HCl and centrifuged at 14,000
rpm for 10 min at 4 °C. The supernatant was split and analyzed
by a spectrophotometer (415 nm). Protein concentrations were
determined by BCA assay (Pierce).
Glucose versus FattyAcidUtilization inVitro—Rat hepatoma
cells were thawed from frozen vials into DMEM/FBS/HS. Cells
were allowed to adhere overnight onto plastic tissue culture
plates and split into 12-well plates (2.5  104 cells/well).
Medium was removed after 24 h, and cells were treated with
high glucose media (20 or 40 mM). The final media contained 0
or 0.5 mM oleic acid, 1% fat-free bovine serum albumin, 0.1 mM
L-carnitine, and 0, 0.1 or 1.0mM etomoxir (Sigma). Glucose and
oleic acid in the media offered cells two sources of calories.
Steady-State Levels of H2O2 per ATP in Bovine Aortic Endo-
thelial Cells—Bovine aortic endothelial cells were plated at 5 
104 cells/well in DMEM/30 mM glucose and HS/FBS for 16 h
followed by DMEM/5 mM glucose for 8 h. Cell medium was
replaced with DMEM/5 mM glucose/1 mM carnitine/0.1 mM
oleate/[14C]oleate/1% bovine serum albumin (fatty acid free).
4-Hydroxycyanocinnamic acid (Bruker) was included in the
final media at concentrations indicated. Cells were harvested
after 8 h to measure steady-state levels of H2O2 by colorimetric
assay (BioAssay Systems) andATP by luminescence assay (Pro-
mega). The media was mixed with perchloric acid (5:1) to iso-
late 14C-labeled acid-soluble metabolites (ketone bodies) and
estimate -oxidation (39).
Statistical Analysis—Student’s t test was used to identify sig-
nificant differences when data within groups showed a normal
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distribution andWilcoxon-Rank Sum test was used when data
did not show a normal distribution. p values less than 0.05 were
considered significant.
RESULTS
Reduced body weight, insulin, glucose, and elevated adi-
ponectin were observed in Snell dwarf mice (Fig. 1). The eleva-
tion of insulin sensitivity in Snell dwarfs is evident on the basis
of the homeostatic model assessment representing the product
of fasting glucose and insulin values divided by a species-spe-
cific constant.
The utilization rate of plasma glucose was 60% lower in
Snell dwarf mice than their litter mate controls (3.6  0.4
versus 9.2  1.0 mg/kg/min, p  0.05, Fig. 2A). During the
measurement of glucose utilization, the stomach of Snell
dwarf and control mice contained small amounts of amylase
digestible starch (Fig. 2B). Therefore, in addition to gluconeo-
genesis and glycogenolysis, the absorption of glucose from the
gastrointestinal tract may have contributed to the production
of plasma glucose. Snell dwarf and control mice were 21–25%
body fat by magnetic resonance imaging. The level of radioac-
tivity measured in plasma after 3H2O injection supported that
percent body fat was similar between Snell dwarf and control
mice. We further investigated (a) the mechanisms that sup-
pressed glucose utilization and (b) the possible link between
low glucose utilization and longevity.
Low utilization of plasma glucose indicates a low rate of glu-
cose production is needed tomaintain a stable concentration of
circulating glucose. Thus, we inquired whether the production
of plasma glucose was suppressed by the inhibition of glucono-
genesis and glycogenolysis, themain sources of glucose in the
fasting state. 2H labeling of plasma glucose by 2H2O indi-
cated that 50% of endogenous glucose production was
derived by gluconeogenesis and 50% by glycogenolysis in
both Snell dwarf and control mice. Therefore, glucose pro-
duction in Snell dwarf mice was suppressed by a mechanism
that did not change the percentage of glucose from glucone-
ogenesis and glycogenolysis.
Low fasting glucose utilization in Snell dwarfs was consid-
ered to be an effect of elevated adiponectin as seen in adiponec-
tin transgenic mice (Fig. 2A). The possibility that adiponec-
tin contributed to the suppression of glucose utilization was
tested further in hepatoma cells exposed to 3T3-L1ACMeither
with or without adiponectin (ACM-adiponectin). Adiponectin
did not suppress glucose production in cells expressing a dom-
inant negative form of AMPK (Fig. 3B). Isotope labeling of glu-
cose by 2H2O indicated that 16% of glucose in the media was
produced by gluconeogenesis regardless of whether cells were
exposed to ACM or ACM-adiponectin (Fig. 3C). Thus, adi-
ponectin suppressed glucose production in vitro without
changing the percent glucose produced from gluconeogenesis
and glycogenolysis.
FIGURE 1. Physiologic features of long-lived Snell dwarf mice. A, body
weight; B, insulin; C, glucose; and D, adiponectin for control and Snell dwarf
mice. Mice were denied access to food at 7 a.m. Measurements were made at
1–3 p.m. Bars represent mean  S.E. (n  6). *, significant difference between
Snell dwarf and control mice (p  0.05).
FIGURE 2. Low fasting glucose utilization in Snell dwarf and adiponectin
transgenic mice. A, fasting glucose utilization was determined by [3H]glu-
cose injection. Bars represent mean  S.E. (n  6). *, significant difference
between mutant and control (ctl) mice (p  0.05). B, glucose in the stom-
ach contents of control and Snell dwarf mice. Bars represent mean  S.E.
(n  4). * and **, significantly different from group shown immediately to
the left (p  0.05).
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The utilization rate of oleic acid, a long-chain fatty acid, was
higher in Snell dwarf mice than control mice (Fig. 4A). Oleic
acid utilization was determined by measuring the disappear-
ance of radioactivity in plasma after trace amounts of [14C]oleic
acid were injected into the circulation. GC/MS analysis
revealed that oleic acid represented 15–16% of circulating fatty
acids in both Snell dwarf and control mice. Other indications
that fatty acid oxidation was elevated in Snell dwarfs included
the reduction of intracellular triacylglyceride contents in liver
and heart (Fig. 4B) and elevated ACC phosphorylation in the
liver (Fig. 4C).
In comparison to control mice, Snell dwarfs showed a
reduction in the protein carbonyl content of the liver (Fig.
5A). The protein carbonyl content in hepatoma cells was
increased by elevated glucose and the absence of fatty acids
in themedia. The protein carbonyl content in hepatoma cells
was also elevated by etomoxir, an inhibitor of fatty acid oxi-
dation (Fig. 5B).
Our observations in Snell dwarfs and hepatoma cells sug-
gested that the switch from glucose to fatty acid utilization after
foodwithdrawalmay reduce oxygen radical production.We are
unaware of any previous studies that testedwhether the aerobic
metabolism of glucose can lead to greater oxygen radical pro-
duction than the aerobic metabolism of fatty acids. Thus, we
also measured steady-state levels of H2O2 per ATP in primary
bovine aortic endothelial cells. 4-OHCA, a pyruvate transport
FIGURE 3. Adiponectin inhibits glucose production by AMPK but does not
change the percent glucose produced by gluconeogenesis. A, Western
blot analysis showing adiponectin in 3T3-L1 adipocyte-conditioned media
(ACM). The first lane (left) shows adiponectin immunoprecipitated from 1 ml
of ACM. The second lane shows the absence of adiponectin after immuno-
precipitation from ACM (ACM-adiponectin). The remaining lanes show 6,
12, 25, 50, 100, and 200 ng of recombinant murine adiponectin. B, adi-
ponectin cannot suppress glucose production in vitro without AMPK. Hep-
atoma cells were transfected with retrovirus encoding either EGFP (white)
or EGFP and dominant negative AMPK (DN-AMPK, black). Bars represent
mean  S.E. (n  3). *, significant difference between ACM and ACM-
adiponectin (p  0.05). C, percent glucose produced by gluconeogenesis
does not differ between ACM and ACM-adiponectin exposure. Bars repre-
sent mean  S.E. (n  3).
FIGURE 4. High fatty acid utilization in fasting Snell dwarf mice. A, fasting
long-chain fatty acid utilization determined by [14C]oleic acid injection. Bars
represent mean  S.E. (n  5). *, significant difference between controls and
Snell dwarfs (p  0.05). B, low intracellular triacylglyceride content in Snell
dwarf liver and heart. Each bar represents mean  S.E. (n  5). *, significant
difference between controls and Snell dwarfs (p  0.05). C, elevated ACC
phosphorylation in Snell dwarf livers by Western blot analysis. Significant
increases in ACC phosphorylation (normalized to total ACC) were observed in
Snell dwarfs by densitometry (p  0.05).
Glucose Utilization and Longevity
NOVEMBER 30, 2007 • VOLUME 282 • NUMBER 48 JOURNAL OF BIOLOGICAL CHEMISTRY 35073
inhibitor, lowered H2O2 per ATP (Fig. 5C). 4-OHCA increased
fatty acid oxidation, estimated by ketone body production (data
not shown).
The reduction of circulating glucose in Snell dwarf mice also
led us to examine whether the frequency of glycations, nonen-
zymatic glycosylation reactions associated with diabetic com-
plications and aging, was decreased. However, hemoglobin
A1c, produced by the glycation of N-terminal valines on the
-chain of hemoglobin, was similar in Snell dwarf and control
mice (4–5%).
DISCUSSION
Our tracer analysis indicates that fasting glucose utilization is
reduced in long-lived Snell dwarf mice. Fasting glucose utiliza-
tion may be reduced by several mechanisms. Low insulin in
Snell dwarfs can decrease insulin-mediated utilization of glu-
cose by insulin-responsive tissues, mainly muscle and adipose
(40, 41). Growth hormone, insulin-like growth factor-1, and
thyroid hormone deficiency in Snell dwarfs can lower tissue
demand for glucose (42, 43). A decrease in the production of
plasma glucose may also lower fasting glucose utilization
(26, 44).
The elevation of adiponectin in Snell dwarf mice may
increase insulin inhibition of glucose production and thereby
contribute to the reduction of fasting glucose utilization. Eug-
lycemic clamp experiments previously showed that rapid eleva-
tion of adiponectin, 3-fold over baseline, increases insulin inhi-
bition of glucose production without altering insulin-mediated
glucose uptake (15). Euglycemic clamp experiments showed
the same result in adiponectin transgenic mice that exhibit a
chronic 3-fold elevation of adiponectin (16). The reduction of
fasting glucose utilization observed in adiponectin transgenic
mice, in the present study, suggests that the 3-fold elevation of
adiponectin in Snell dwarfs is exerting an inhibitory effect on
glucose production during fasting (Fig. 2A). In vitro data, pre-
sented here and elsewhere, obtained under conditions that
resemble the fasting state (low glucose and insulin), support the
hypothesis that adiponectin lowers glucose production during
fasting (14).
Glucose production can be suppressed by the reduction of
gluconeogenesis or glycogenolysis (45, 46). Our in vivo isotope
labeling analysis indicated that the suppression of glucose pro-
duction in Snell dwarfs is mediated without any change in the
percent glucose from gluconeogenesis and glycogenolysis.
Our in vitro isotope-labeling studies also indicated that adi-
ponectin lowers glucose production without altering the
percent glucose from gluconeogenesis and glycogenolysis.
Thiazolidinediones, pharmacologic agents widely pre-
scribed for the treatment of insulin resistance in type-2 dia-
betics, increase adiponectin and lower fasting glucose utili-
zation (47, 48). These observations support that elevated
adiponectin may contribute to the reduction of glucose pro-
duction in Snell dwarfs and possibly other long-lived models
that exhibit elevated adiponectin (17, 18).
Previous studies in mice show that adiponectin suppression
of glucose production can be blocked by the ablation of the
AMPK gene (49). We showed that the inhibition of glucose
production by adiponectin in vitro was blocked by the expres-
sion of a dominant negative AMPKmutant (36). Studies in iso-
lated hepatocytes showed the inhibition of AMPK can block
adiponectin suppression of mRNA encoding phosphoenol-
pyruvate carboxykinase and glucose-6-phosphatase, two rate-
limiting enzymes in gluconeogenesis (20).
AMPK activation by adiponectin may also play a role in the
elevation of fatty acid utilization in Snell dwarf mice. AMPK
phosphorylates ACC and malonyl-CoA decarboxylase, low-
ering malonyl-CoA, a precursor in fatty acid synthesis and
potent inhibitor of mitochondrial carnitine palmitoyltrans-
FIGURE 5. Protein carbonyl content, a marker of oxygen radical dam-
age, is decreased in Snell dwarf mice and elevated in vitro by high
glucose utilization. A, liver protein carbonyl content in Snell dwarf and
control mice. Bars represent mean  S.E. (n  6 –7). *, significant differ-
ence between Snell dwarfs and controls (p  0.05). B, protein carbonyl
content in rat hepatoma cells exposed to the indicated concentrations of
glucose, oleic acid, and etomoxir, an inhibitor of fatty acid oxidation. Bars
represent mean  S.E. (n  3). *, significantly different from high glucose/
fatty acid free media (p  0.05); **, significantly different than lower con-
centrations of etomoxir (p  0.05). C, steady-state levels of H2O2 per ATP in
primary bovine aortic endothelial cells. 4-OHCA, a pyruvate transport
inhibitor used to block the aerobic metabolism of glucose, lowered H2O2
production per ATP. Bars represent mean  S.E. (n  3). *, significantly
different from control (p  0.05); **, significantly different from lower
concentration of 4-OHCA (p  0.05).
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ferase-1, the long-chain fatty acyl-CoA transporter (50). In
the present study, increased phosphorylation of ACC is con-
sistent with the elevation of fatty acid utilization and the
reduction of intracellular lipid stores in Snell dwarf liver and
heart (Fig. 4). Gene expression array data in Snell dwarf
and other long-lived mice, including the Ames dwarf, little,
and growth hormone receptor-null mice, support the con-
clusion that fatty acid oxidation is elevated in these long-
lived mice (51).
Whether the aerobic metabolism of glucose leads to more
oxygen radical production than fatty acid oxidation is not
known. We present three results that suggest glucose and fatty
acid oxidation could differentially affect oxygen radical produc-
tion: 1) low glucose and high fatty acid utilization correlated
with a low level of oxygen radical damage in Snell dwarf mice
(Fig. 5A), 2) oxygen radical damage increasedwith the elevation
of glucose, the absence of fatty acids from the media and
pharmacologic inhibition of fatty acid oxidation in hepa-
toma cells (Fig. 5B), and 3) pharmacologic inhibition of glu-
cose oxidation lowered H2O2 per ATP in bovine aortic endo-
thelial cells (Fig. 5C).
Aerobic metabolism of nutrients for ATP is associated with
oxygen radical production and secondary chemical modifica-
tions of DNA, lipids, and proteins, potentially accelerating
aging (52). Oxygen radicals modify the side chains of lysine,
arginine, proline, and histidine residues, resulting in the
appearance of protein carbonyl groups, a chemical modifica-
tion that increases with aging (53). In the present study,
reduced protein carbonyl content in Snell dwarf mouse liver is
consistent with a decrease in oxygen radical production (Fig.
5A). Other studies also indicate that oxidative damage is
reduced in Snell dwarfs. (54, 55).
Our data in hepatoma cells suggest that high glucose utiliza-
tion can increase oxygen radical levels in vitro (Fig. 5B). We
raised glucose utilization by increasing the concentration of
glucose and reducing the concentration of fatty acids in the
media or adding etomoxir, an inhibitor of fatty acid oxidation
and stimulator of glucose utilization (56). Etomoxir effects in
HepG2 cells support that the reduction of fatty acid utilization
elevates oxygen radical damage (57).
Superoxide anions are produced during ATP production by
oxidative phosphorylation as electrons from NADH and
FADH2 leak across the inner mitochondrial membrane and react
directly with O2, forming superoxide, instead of with O2 and
hydrogen ions to form water (58). Hydrogen peroxide (H2O2) is
formed from superoxide anions by superoxide dismutase (59).
In bovine aortic endothelial cells, 4-OHCA, an inhibitor of glu-
cose oxidation, lowered H2O2 per ATP (Fig. 5C). Energy from
glucose metabolism may generate more superoxide anions
than fatty acid metabolism, because 1) NADH is oxidized by
complex I, the site of highest electron leakage and superox-
ide anion synthesis and 2) glucose is oxidized by a higher
NADH to FADH2 ratio (60–62). Glucose yields 38 ATP from
anNADH to FADH2 ratio of 10:2 {4 ATP from substrate level
phosphorylation (2 by glycolysis, 2 by Krebs cycle), 30 ATP
from 10 NADH (2 by glycolysis and 8 by Krebs cycle), and 4
ATP from 2 FADH2 (2 by Krebs cycle)}. Palmitic acid, a
long-chain fatty acid, yields 112 ATP from an NADH to
FADH2 ratio of 28:14 {84 ATP from 28 NADH (7 by -oxi-
dation, 21 by Krebs cycle) and 28 ATP from 14 FADH2 (7 by
-oxidation, 7 by Krebs cycle)}. Fatty acids also activate
uncoupling proteins, which reduce oxygen radical produc-
tion by depolarizing the inner mitochondrial membrane
(63). A shift in substrate utilization may underlie the reduc-
tion of oxygen radical production in human myotubes
exposed to adiponectin (64). However, further research is
needed to resolve whether ATP production from glucose is
actually a greater source of oxygen radicals than ATP pro-
duction from fatty acids.
The suppression of glucose utilization in Snell dwarf mice
was also linked to the reduction of circulating glucose. In clin-
ical studies, both fasting glucose and hemoglobin A1c
increase with aging even in the absence of diabetes (65).
Thus, we postulated that the reduction of circulating glucose
in the long-lived mice may reduce the frequency of glyca-
tions. A previous study showed that both circulating glucose
and hemoglobin A1c are reduced in young calorie restricted
rats (66). However, in the present study hemoglobin A1c was
4–5% in both Snell dwarf and control mice. We did not
check the levels of N-carboxymethyllysine, pentosidine, or
methylglyoxal to confirm that other glycation end-products
were not reduced in Snell dwarfs.
Our measurements of fasting glucose utilization represent
the first data obtained by a single injection of [3H]glucose in
mice. This method shows that fasting glucose utilization in
mice is 10 mg/kg/min. Fasting glucose utilization values
obtained by constant infusion of [3H]glucose, a widely used
technique, tend to be higher. Fasting glucose utilization values
may be higher when measured by constant infusion of tracer
because of the surgery needed to insert an intravenous catheter
into a mouse. After all, elevated carbohydrate metabolism and
insulin resistance are characteristic features of the surgical
recovery phase (67). The administration of anticoagulants,
needed to maintain an open catheter in mice, may also
increase carbohydrate metabolism, because anticoagulants,
like heparin, disrupt cell-associated lipoprotein lipase activ-
ity and can thereby lower fatty acid metabolism (68). These
factors may not be an issue when intravenous catheters are
used in larger organisms.
Many studies suggest that energy expenditure per unit body
weight does not differ between long-lived and controlmice. For
example, based on daily food intake, the average energy
expenditure in Ames dwarf mice and control mice is 325 cal/
kg/min (69). Our measurements indicate that fasting glucose
utilization inmice is10mg/kg/min (40 cal/kg/min). Thus, we
estimate that fasting glucose utilization accounts for 15–20% of
the total daily energy expenditure in control mice and 5–7% in
Snell dwarfs. The concept that total energy expenditure per
bodyweight is not reduced in long-livedmodels is corroborated
in calorie restricted rats (70).
In summary, Snell dwarf mice exhibit reduced glucose utili-
zation and elevated fatty acid utilization during fasting. High
levels of circulating adiponectinmay contribute to the switch in
substrate utilization. The reduction of glucose utilization and
elevation of fatty acid utilization during fasting may increase
Glucose Utilization and Longevity
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longevity in Snell dwarf mice by decreasing oxygen radical
production.
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